HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis - Summary - MDSpire

HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis

  • By

  • Joseph Fokam

  • Aude Christelle Ka’e

  • Bouba Yagai

  • Maria Mercedes Santoro

  • Judith Kose Otieno

  • Natella Rakhmanina

  • Collins Ambe Chenwi

  • Alex Durand Nka

  • Ezechiel Ngoufack Jagni Semengue

  • Davy-Hyacinthe Gouissi

  • Willy Leroi Pabo Togna

  • Nelly Kamgaing

  • Tetang Suzie

  • Desire Takou

  • Georges Teto

  • Tatiana Tekoh

  • Jeremiah Efakika Gabisa

  • Audrey Nayang Mundo

  • Lum Forgwei

  • Naomi-Karell Etame

  • Aurelie Minelle Kengni Ngueko

  • Michel Carlos Tommo Tchouaket

  • Boris Tchounga

  • Patrice Tchendjou

  • Joelle Nounouce Bouba Pamen

  • Rogers Ajeh Awoh

  • Gregory-Edie Halle-Ekane

  • Giulia Cappelli

  • Alexis Ndjolo

  • Francesca Ceccherini-Silberstein

  • Vittorio Colizzi

  • Jean Kaseya

  • Nicaise Ndembi

  • Carlo Federico Perno

  • June 26, 2025

  • 0 min

Share

Objective:

To assess the global pooled prevalence of pretreatment drug resistance (PDR) and acquired drug resistance (ADR) in children with HIV (CWHIV) and associated factors over the past decade (2010-2020).

Key Findings:
  • PDR prevalence was 32.48% (95% CI: 26.08–39.21), higher among those who failed PMTCT (43.23% [95% CI: 32.94–53.82]).
  • ADR prevalence was 61.43% (95% CI: 49.82–72.45), predominantly driven by NNRTI mutations (65.17% [95% CI: 53.95–75.63]).
  • INSTI-ADR was low at 5.53% (95% CI: 2.49–9.53) but emerging.
Interpretation:

High burdens of PDR and ADR among CWHIV indicate a pressing need to phase out pediatric NNRTIs and enhance drug-resistance surveillance strategies.

Limitations:
  • Limited treatment options and coverage for CWHIV, impacting the generalizability of findings.
  • Challenges in LMICs including drug stock-outs and inadequate dosing guidelines, which may exacerbate drug resistance.
Conclusion:

The findings underscore the urgent need to address drug resistance in pediatric HIV treatment to improve health outcomes and achieve global HIV elimination targets.

Original Source(s)

HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis

  • by Joseph Fokam, Aude Christelle Ka’e, Bouba Yagai, Maria Mercedes Santoro, Judith Kose Otieno, Natella Rakhmanina, Collins Ambe Chenwi, Alex Durand Nka, Ezechiel Ngoufack Jagni Semengue, Davy-Hyacinthe Gouissi, Willy Leroi Pabo Togna, Nelly Kamgaing, Tetang Suzie, Desire Takou, Georges Teto, Tatiana Tekoh, Jeremiah Efakika Gabisa, Audrey Nayang Mundo, Lum Forgwei, Naomi-Karell Etame, Aurelie Minelle Kengni Ngueko, Michel Carlos Tommo Tchouaket, Boris Tchounga, Patrice Tchendjou, Joelle Nounouce Bouba Pamen, Rogers Ajeh Awoh, Gregory-Edie Halle-Ekane, Giulia Cappelli, Alexis Ndjolo, Francesca Ceccherini-Silberstein, Vittorio Colizzi, Jean Kaseya, Nicaise Ndembi, Carlo Federico Perno

  • June 26, 2025

Related Content

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Case Report and retrospective literature analysis of pediatric lower esophageal squamous cell carcinoma: focus on diagnostic challenges and therapeutic strategies

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility